Xenon Pharmaceuticals Reveals Promising Epilepsy Drug Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2024
0mins
Should l Buy XENE?
Source: Business Insider
Xenon Pharmaceuticals Update: Xenon has released long-term data from its X-TOLE study, demonstrating that its drug azetukalner significantly reduces seizure frequency in patients with focal onset seizures, with one-third achieving complete seizure freedom after over three years of treatment.
Investment Opportunity: TipRanks is offering a 40% discount on its Premium service, which provides expert stock picks and insights for smarter investing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XENE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XENE
Wall Street analysts forecast XENE stock price to fall
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 62.760
Low
44.00
Averages
54.09
High
62.00
Current: 62.760
Low
44.00
Averages
54.09
High
62.00
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
- Clinical Trial Success: Xenon's X-TOLE2 study demonstrated that azetukalner achieved its primary endpoint in treating focal onset seizures, with a placebo-adjusted MPC of -42.7% in the 25 mg group, significantly outperforming the previous Phase 2b study's -34.6%, indicating a potential shift in epilepsy treatment paradigms.
- Good Safety Profile: Azetukalner exhibited a safety and tolerability profile consistent with prior studies, suggesting its feasibility in clinical applications and enhancing investor confidence in the drug's future market performance.
- Future Plans: Xenon intends to submit a New Drug Application (NDA) to the FDA in Q3 2026, and if approved, azetukalner would be the only KV7 potassium channel opener available, further solidifying the company's market position in epilepsy treatment.
- Study Scale: The X-TOLE2 clinical trial enrolled 380 participants using a randomized, double-blind, placebo-controlled design, ensuring the reliability and scientific validity of the results, thereby laying a solid foundation for azetukalner's market launch.
See More
Xenon Pharmaceuticals Stock Soars 44% Following Successful Late-Stage Trial of Epilepsy Drug
Stock Surge: Xeno Pharmaceuticals shares increased by 44% following positive developments related to their epilepsy drug.
Clinical Trial Success: The surge in stock is attributed to the drug meeting its main goals in a late-stage trial, indicating promising results for future market potential.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a significant impact on the short-term performance of the affected stocks, prompting investors to pay close attention to these adjustments.
- Market Reaction Expectations: The adjustments in analyst ratings may lead to increased attention on AZO stock, as investors reassess their strategies based on these changes, potentially affecting trading volumes and price fluctuations.
- Source Reliability: The market news and data provided by Benzinga serve as a crucial reference for investors; although it does not offer investment advice, its analyst ratings page provides a comprehensive view of rating changes for informed decision-making.
See More
Xenon Pharmaceuticals Stock Surpasses Analyst Target Price
- Price Target Breakthrough: Xenon Pharmaceuticals' stock has reached $62.67, surpassing the analyst's 12-month target price of $56.39, indicating market optimism about the company's prospects, which may prompt analysts to reassess their target prices.
- Analyst Target Distribution: Among the 19 analysts covered by Zacks, target prices range from $47.00 to $66.00, with a standard deviation of $5.468, reflecting significant variance in market expectations and differing views on the company's future performance.
- Investor Signal: The stock's breach of the target price provides investors with an opportunity to reassess Xenon Pharmaceuticals, prompting them to consider whether the current valuation is justified or if they should take profits to mitigate risk.
- Market Reaction Analysis: Analysts' reactions could influence stock price movements; if the majority opt to raise their target prices, it may further drive the stock price up, while downgrades could lead to a price pullback.
See More
Xenon Plans New Drug Application Submission
- Trial Results Exceed Expectations: Xenon announced that its azetukalner showed a median percent change of 53.2% in monthly focal onset seizure frequency at the 25 mg dose, significantly outperforming the placebo's 10.4%, which not only validates the drug's efficacy but also lays a solid foundation for future FDA submissions.
- New Drug Application Plans: The company plans to submit a new drug application for azetukalner to the U.S. FDA in Q3 2026, with CEO Ian Mortimer stating that the trial results “exceeded expectations,” potentially reshaping the epilepsy treatment landscape to meet the needs of 50% of patients seeking better control.
- Positive Market Reaction: Following the trial data announcement, Xenon's stock surged 50%, with Jefferies and RBC Capital raising their price targets to $100 and $80 respectively, reflecting strong market confidence in azetukalner and its significant sales potential in the future.
- Competitor Dynamics: Despite Biohaven's opakalim having safety disadvantages, Raymond James maintains a ‘Strong Buy’ rating, anticipating pivotal trial results in H2 2026 that will further clarify its market positioning.
See More
Xenon and Relmada Surge on Positive Drug Data
- Xenon Drug Breakthrough: Xenon Pharmaceuticals' azetukalner achieved a 53.2% reduction in seizure frequency in the Phase 3 X-TOLE2 study, with an NDA submission to the FDA targeted for the second half of 2026, significantly enhancing the company's commercialization prospects.
- Strong Financial Backing: Xenon currently holds $716 million in cash, providing a runway into the second half of 2027, which mitigates near-term financing risks and supports the new drug application process.
- Relmada Therapy Progress: Relmada Therapeutics' NDV-01 demonstrated a 92% complete response rate in 12-month data for non-muscle-invasive bladder cancer, with two Phase 3 trials expected to initiate in the first half of 2026, further solidifying its market position.
- Massive Market Potential: Relmada's NDV-01 is projected to achieve peak sales of $2.3 billion, with a current market cap of approximately $525 million, indicating strong growth potential that is attracting investor interest.
See More
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
- Clinical Trial Success: Xenon's X-TOLE2 study demonstrated that azetukalner achieved its primary endpoint in treating focal onset seizures, with a placebo-adjusted MPC of -42.7% in the 25 mg group, significantly outperforming the previous Phase 2b study's -34.6%, indicating a potential shift in epilepsy treatment paradigms.
- Good Safety Profile: Azetukalner exhibited a safety and tolerability profile consistent with prior studies, suggesting its feasibility in clinical applications and enhancing investor confidence in the drug's future market performance.
- Future Plans: Xenon intends to submit a New Drug Application (NDA) to the FDA in Q3 2026, and if approved, azetukalner would be the only KV7 potassium channel opener available, further solidifying the company's market position in epilepsy treatment.
- Study Scale: The X-TOLE2 clinical trial enrolled 380 participants using a randomized, double-blind, placebo-controlled design, ensuring the reliability and scientific validity of the results, thereby laying a solid foundation for azetukalner's market launch.
See More
Xenon Pharmaceuticals Stock Soars 44% Following Successful Late-Stage Trial of Epilepsy Drug
Stock Surge: Xeno Pharmaceuticals shares increased by 44% following positive developments related to their epilepsy drug.
Clinical Trial Success: The surge in stock is attributed to the drug meeting its main goals in a late-stage trial, indicating promising results for future market potential.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a significant impact on the short-term performance of the affected stocks, prompting investors to pay close attention to these adjustments.
- Market Reaction Expectations: The adjustments in analyst ratings may lead to increased attention on AZO stock, as investors reassess their strategies based on these changes, potentially affecting trading volumes and price fluctuations.
- Source Reliability: The market news and data provided by Benzinga serve as a crucial reference for investors; although it does not offer investment advice, its analyst ratings page provides a comprehensive view of rating changes for informed decision-making.
See More
Xenon Pharmaceuticals Stock Surpasses Analyst Target Price
- Price Target Breakthrough: Xenon Pharmaceuticals' stock has reached $62.67, surpassing the analyst's 12-month target price of $56.39, indicating market optimism about the company's prospects, which may prompt analysts to reassess their target prices.
- Analyst Target Distribution: Among the 19 analysts covered by Zacks, target prices range from $47.00 to $66.00, with a standard deviation of $5.468, reflecting significant variance in market expectations and differing views on the company's future performance.
- Investor Signal: The stock's breach of the target price provides investors with an opportunity to reassess Xenon Pharmaceuticals, prompting them to consider whether the current valuation is justified or if they should take profits to mitigate risk.
- Market Reaction Analysis: Analysts' reactions could influence stock price movements; if the majority opt to raise their target prices, it may further drive the stock price up, while downgrades could lead to a price pullback.
See More
Xenon Plans New Drug Application Submission
- Trial Results Exceed Expectations: Xenon announced that its azetukalner showed a median percent change of 53.2% in monthly focal onset seizure frequency at the 25 mg dose, significantly outperforming the placebo's 10.4%, which not only validates the drug's efficacy but also lays a solid foundation for future FDA submissions.
- New Drug Application Plans: The company plans to submit a new drug application for azetukalner to the U.S. FDA in Q3 2026, with CEO Ian Mortimer stating that the trial results “exceeded expectations,” potentially reshaping the epilepsy treatment landscape to meet the needs of 50% of patients seeking better control.
- Positive Market Reaction: Following the trial data announcement, Xenon's stock surged 50%, with Jefferies and RBC Capital raising their price targets to $100 and $80 respectively, reflecting strong market confidence in azetukalner and its significant sales potential in the future.
- Competitor Dynamics: Despite Biohaven's opakalim having safety disadvantages, Raymond James maintains a ‘Strong Buy’ rating, anticipating pivotal trial results in H2 2026 that will further clarify its market positioning.
See More
Xenon and Relmada Surge on Positive Drug Data
- Xenon Drug Breakthrough: Xenon Pharmaceuticals' azetukalner achieved a 53.2% reduction in seizure frequency in the Phase 3 X-TOLE2 study, with an NDA submission to the FDA targeted for the second half of 2026, significantly enhancing the company's commercialization prospects.
- Strong Financial Backing: Xenon currently holds $716 million in cash, providing a runway into the second half of 2027, which mitigates near-term financing risks and supports the new drug application process.
- Relmada Therapy Progress: Relmada Therapeutics' NDV-01 demonstrated a 92% complete response rate in 12-month data for non-muscle-invasive bladder cancer, with two Phase 3 trials expected to initiate in the first half of 2026, further solidifying its market position.
- Massive Market Potential: Relmada's NDV-01 is projected to achieve peak sales of $2.3 billion, with a current market cap of approximately $525 million, indicating strong growth potential that is attracting investor interest.
See More
